[CAS NO. 123-99-9] Azelaic acid

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [123-99-9]

Catalog

HY-B0704

Brand

MCE

CAS

123-99-9

DESCRIPTION [123-99-9]

Overview

MDL	MFCD00004432
Molecular Weight	188.22
Molecular Formula	C9H16O4
SMILES	OC(CCCCCCCC(O)=O)=O

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]Katedra farmakologie a toxikologie. 2020 Jul.

Summary

Azelaic acid is an organic compound produced by the ozonolysis of oleic acid; component of a number of hair and skin conditioners.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03094403	Taro Pharmaceuticals USA	Rosacea	July 1, 2016	Phase 1
NCT02120924	Actavis Inc.	Rosacea	July 2013	Phase 3
NCT00617903	LEO Pharma\|Bayer	Papulopustular Rosacea	January 2008	Phase 2
NCT00403949	LEO Pharma\|Bayer	Perioral Dermatitis	November 2006	Phase 2
NCT03418610	Clinical Research Center of the Carolinas\|Bayer	Rosacea, Papulopustular	December 6, 2017	Phase 4
NCT00031096	LEO Pharma\|Bayer	Acne Vulgaris	January 2002	Phase 3
NCT02602470	LEO Pharma\|Bayer	Rosacea	January 8, 2015
NCT03689010	Taro Pharmaceuticals USA	Rosacea	December 12, 2017	Phase 1
NCT01659853	Galderma R&D	Erythema\|Rosacea	September 2012	Phase 3
NCT01493687	Galderma R&D	Papulopustular Rosacea (PPR)	December 2011	Phase 3
NCT01555463	LEO Pharma\|Bayer	Papulopustular Rosacea	September 2012	Phase 3
NCT01850095	Marco Alexandre Dias da Rocha\|Fleury\|Associacao Fundo de Incentivo a Psicofarmcologia\|Bayer\|Federal University of São Paulo	Acne\|Quality of Life	March 2012	Not Applicable
NCT00408330	LEO Pharma\|Bayer	Seborrheic Dermatitis on the Face	December 2006	Phase 2
NCT01631656	Wake Forest University Health Sciences\|Bayer	Rosacea	July 2010	Not Applicable
NCT03193372	LEO Pharma\|Bayer	Rosacea	July 20, 2017
NCT03287791	Actavis Inc.	Rosacea	July 19, 2016	Phase 3
NCT01430533	LEO Pharma\|Bayer	Healthy	September 2011	Phase 1
NCT02800148	Padagis LLC\|DPT Laboratories, Ltd.	Rosacea	November 2016	Phase 3
NCT00848458	Medical University of Vienna	Melasma	January 2009	Phase 2\|Phase 3
NCT00927771	Callender Center for Clinical Research	Melanosis	June 2009	Phase 4
NCT05416333	Wake Forest University Health Sciences	Central Centrifugal Cicatricial Alopecia	November 2022	Early Phase 1
NCT01430312	LEO Pharma\|Bayer	Healthy	September 2011	Phase 1
NCT02058628	GlaxoSmithKline	Acne Vulgaris	February 21, 2014	Phase 4
NCT01494467	Galderma R&D	Papulopustular Rosacea	December 2011	Phase 3
NCT00855595	LEO Pharma\|Bayer	Papulopustular Rosacea	February 2009	Phase 4
NCT01139047	Galderma R&D	Skin Manifestations	June 2010	Phase 4
NCT02147691	Derm Research, PLLC\|Bayer Healthcare Pharmaceuticals, Inc.+Bayer Schering Pharma	Acne Rosacea	May 2014	Phase 4
NCT01139008	Galderma R&D	Skin Manifestations	June 2010	Phase 4
NCT00417937	LEO Pharma\|Bayer	Papulopustular Rosacea	January 2007	Phase 4
NCT05014906	Dermatology Specialists Research	Rosacea	May 2010	Phase 4
NCT03035955	Wake Forest University\|Wake Forest University Health Sciences	Rosacea	December 2010	Phase 2\|Phase 3
NCT01257919	LEO Pharma\|Bayer	Papulopustular Rosacea	January 2011	Phase 1
NCT01038869	Derm Research, PLLC\|Bayer	Acne Vulgaris\|Post Inflammatory Hyperpigmentation	December 2009	Phase 4
NCT01025635	LEO Pharma\|Bayer	Papulopustular Rosacea	December 2009	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL ( 531.29 mM )

H ₂ O : 2 mg/mL ( 10.63 mM ; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.3129 mL	26.5647 mL	53.1293 mL
5 mM	1.0626 mL	5.3129 mL	10.6259 mL
10 mM	0.5313 mL	2.6565 mL	5.3129 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (13.28 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (13.28 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (13.28 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Nonanedioic acid

Azelaic acid

Anchoic acid

1,7-Heptanedicarboxylic acid

Lepargylic acid

Emerox 1144

1,9-Nonanedioic acid

1,7-Dicarboxyheptane

n-Nonanedioic acid

Emery 1110

ZK 62498

Skinoren

Empol 1144

NSC 19493

Finacea

Emery 1144

Azelic acid

α,ω-Nonanedioic acid

Aziderm